Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Rang in Aktien #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Aktienkurs
$0.11725176
Zuletzt synchronisiert: 2025-07-14
Marktkapitalisierung
$481.50K
Veränderung (1 Tag)
-0.20%
Veränderung (1 Jahr)
0.00%
Land
FR
Handel PHAXIAM Therapeutics S.A. (PHXM)

Kategorie

Kursverlauf für PHAXIAM Therapeutics S.A. (PHXM)
Höchster Schlusskurs: $0.12 am 2025-07-01

Niedrigster Schlusskurs: $130.13 am 2013-05-01
Kursverlauf der Aktie von PHAXIAM Therapeutics S.A. von 2013 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2025 -93.43%
2024 -61.15%
2023 -4.10%
2022 -78.67%
2021 -73.09%
2020 82.18%
2019 -31.14%
2018 -67.04%
2017 59.44%
2016 -51.03%
2015 -15.90%
2014 158.90%
2013 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$517.18 32.51%
US
$857.76 31.47%
NL
$735.86 7.74%
CH
$1.07K -6.40%
KR
$257.99 13.97%
BE